Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts: a retrospective single-center experience

Ähnliche Einträge

• Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia
  von: Ottmann, Oliver G., et al.
  Veröffentlicht: (2019)
• Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis
  von: Frühauf, Stefan, et al.
  Veröffentlicht: (2007)
• Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
  von: Platzbecker, Uwe, et al.
  Veröffentlicht: (2018)
• Charcot-Leyden crystals and bone marrow necrosis in acute myeloid leukemia
  von: Radujković, Aleksandar, et al.
  Veröffentlicht: (2011)
• Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia
  von: Radujković, Aleksandar, et al.
  Veröffentlicht: (2017)